Press Release

Eureka Therapeutics Announces Appointment Of Dr. Hanzhong Li As Senior Vice President Of Corporate Development

EMERYVILLE, California, February 11, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong Li, Ph.D., M.B.A. as Senior Vice President of Corporate Development.

“It is my pleasure to welcome Hanzhong to Eureka,” said Cheng Liu, Ph.D., President and Chief Executive Officer of Eureka. “Hanzhong is an industry expert with a rare blend of insights into the biotech industry and deep relationships within the financial community. We are very fortunate to have him join the Eureka team and look forward to working with him.”

Dr. Li has over twenty years of combined experience in finance, equity research and the biopharmaceutical industry. Prior to joining Eureka, Dr. Li was the Chief Financial Officer of the Ascentage Pharma Group. From 2010 to 2017, Dr. Li served as a Deputy Director in the strategy and portfolio management group at Bayer. Prior to that, Dr. Li served as a biotech analyst at Morgan Stanley, Suntrust Robinson Humphrey, and the Stanford Financial Group. Prior to that, Dr. Li served as a Research Scientist at Genentech where he was a lead inventor of three patents on novel cytokines. Dr. Li holds a Ph.D. in Pharmacology from the Boston University School of Medicine and an M.B.A. in Finance from the University of California, Los Angeles.

“I have been greatly impressed by the transformative technology at Eureka. I believe the early results from Eureka’s first-in-human study of ET140202 ARTEMIS T-cell therapy for hepatocellular carcinoma (HCC) are very promising,” said Dr. Li. “I look forward to helping the company achieve its strategic goals.”

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company developing antibody-TCR (AbTCR) T-Cell Therapies for solid and hematological malignancies. Its core technology centers around its proprietary ARTEMIS™ AbTCR T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors.

Eureka’s lead asset, ET140202, utilizes Eureka’s proprietary ARTEMIS™ T-cell receptor platform engineered with a proprietary human TCR-mimic (TCRm) antibody to target an AFP-peptide/HLA-A2 complex on HCC cancer cells. Data presented in September 2018 from Eureka’s ongoing first-in-human study of ET140202 in China demonstrated a favorable safety profile with no observed cytokine release syndrome or drug-related neurotoxicity. The Company plans to initiate its Phase 1/2 US multicenter clinical trial in the first half of 2019.

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

CONTACTS:

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-722-8720
IR@eurekainc.com